- Home
- EMIS vs BDTX Comparison
EMIS vs BDTX Comparison
Compare EMIS & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
Current Price
$10.00
HOLD
Current Price
$2.58
Company Overview
Basic Information| Metric | EMIS | BDTX |
|---|---|---|
| Founded | 2024 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 157.1M | 148.1M |
| IPO Year | 2025 | 2020 |
Fundamental Metrics
Financial Performance| Metric | EMIS | BDTX |
|---|---|---|
| Price | $10.00 | $2.58 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $10.40 |
| AVG Volume (30 Days) | 39.1K | ★ 964.6K |
| Earning Date | 01-01-0001 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.38 |
| Revenue | N/A | ★ $70,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $6.77 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.90 | $1.20 |
| 52 Week High | $11.11 | $4.94 |
Technical Indicators
Market Signals| Indicator | EMIS | BDTX |
|---|---|---|
| Relative Strength Index (RSI) | 50.65 | 43.82 |
| Support Level | $9.99 | $2.49 |
| Resistance Level | $10.01 | $2.70 |
| Average True Range (ATR) | 0.01 | 0.15 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 35.71 | 40.38 |
Price Performance
Historical Comparison EMIS
BDTX
About EMIS Emmis Acquisition Corp. Class A Ordinary Shares
Emmis Acquisition Corp is a blank check company.
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.